This study focuses on treating patients with locally advanced resectable gastroesophageal adenocarcinoma, which is a type of cancer affecting the stomach and the area where the stomach connects to the esophagus (food pipe). The study will test three experimental medications: Rilvegostomig (also known as AZD2936), trastuzumab deruxtecan (also known as DS-8201a), and AZD0901. These medications will be given through an infusion, which means they will be administered directly into a vein.
The purpose of this research is to evaluate how safe these medications are and how well patients tolerate them when given before and after surgery. The study will also look at how effective the treatments are at fighting the cancer before surgery is performed. During the study, patients will receive the study medications, undergo surgery to remove the cancer, and then continue with additional treatment after surgery.
This is an open-label study, which means both doctors and patients will know which medication is being given. The study will include multiple treatment groups testing different combinations of these medications. Patients will be assigned to specific treatment groups based on certain characteristics of their cancer, including whether their cancer cells have specific markers called CLDN18.2 or HER2.
Italy 
Spain